Table 3.
% change1 | Irinotecan concentration | SN-38 concentration | ||||
---|---|---|---|---|---|---|
(combination vs. drug alone) | Plasma | A253 | FaDu | Plasma | A253 | FaDu |
Concurrent schedule2 | 6 | −13 | −12 | −1 | 44 | −31 |
Sequential schedule (d7)3 | 92*** | 45 | 16 | 23 | 56 | 61 |
Sequential schedule (d14)4 | 32 | ND | −60*** | 23*** | ND | 124*** |
Compared to irinotecan alone
MSC (0.2 mg/mouse) + irinotecan (100mg/kg)
MSC (0.2 mg/mouse/d) 7d prior to and then concurrently with irinotecan (100mg/kg×1)
MSC (0.2 mg/mouse/d) 7d prior to and then concurrently with irinotecan (100mg/kg×2)
p<0.001 when compared with irinotecan alone